Wnt Agonist
Wnt Agonist - Related Videos
13:00
Studying Wnt Signaling During Patterning of Conducting Airways
0 Views •
Cited by 4 •
2016
The use of reporter mice coupled to whole mount and section staining, microscopy and in vivo assays facilitates the analysis of mechanisms underlying the normal patterning of the respiratory tract. Here we describe how these techniques contributed to the analysis of Wnt signaling during tracheal development.
11:45
Quantifying Agonist Activity at G Protein-coupled Receptors
0 Views •
Cited by 10 •
2011
A method for estimating the affinity constant of an agonist for the active state (Kb) of a G protein-coupled receptor is described. The analysis provides absolute or relative measures of Kb depending on whether constitutive receptor activation is measurable. Our method applies to various responses downstream from receptor activation.
02:54
Canonical Wnt Signaling Pathway
0 Views •
2023
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
02:54
Canonical Wnt Signaling Pathway
0 Views •
2021
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
01:24
Glucagon-like Receptor Agonists
0 Views •
2024
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP. GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
FAQs
Inhibition of the GSK-3β-containing destruction complex reduces β-catenin destruction, allowing β-catenin to accumulate. The increased β-catenin can then regulate expression of Wnt target genes, linking pathway activation to changes in cell fate, proliferation, polarity, and tissue patterning. This mechanism gives researchers a way to connect altered signaling activity with developmental outcomes.
Some Wnt agonists act by mimicking Wnt ligands, while others increase pathway activity downstream by preventing β-catenin destruction. These strategies engage the pathway at different points, even though both can elevate Wnt signaling. The distinction helps researchers interpret whether an observed developmental response reflects ligand-like activation or altered control of intracellular β-catenin stability.
β-catenin accumulation provides a molecular link between Wnt pathway activity and developmental gene regulation. Because Wnt signaling influences cell fate, proliferation, polarity, and tissue patterning, changing β-catenin levels can alter how cells and tissues develop. Researchers therefore use agonist-driven pathway activation to examine how signaling changes produce different developmental patterns or cell states.
Researchers can use pathway activation to manipulate whether developmental systems maintain stem cell characteristics or proceed toward differentiation. Comparing systems with altered Wnt activity helps reveal how signaling contributes to these opposing outcomes. This approach is useful for studying developmental decisions and for connecting molecular pathway activity with the formation of specialized cell types.
Wnt agonists provide a means to control Wnt pathway activity during organoid formation. Because Wnt signaling contributes to cell fate and tissue patterning, adjusting this activity can help researchers examine how organized, tissue-like structures develop. Organoid experiments also offer a setting for connecting pathway manipulation with broader questions about developmental organization and regeneration.
Researchers use Wnt agonists to model the consequences of altered Wnt activity in developmental systems. Examining changes in patterning, cell fate, or tissue formation can help investigate how pathway disruption contributes to congenital abnormalities. The same experimental strategy provides context for studying disease-related signaling changes and evaluating the developmental relevance of abnormal pathway activation.